PURPOSE: Pegylated liposomal @entity632 (PLD) is widely used in relapsing @entity43 . Its original formulation is metabolized by the monocyte-macrophage system. One of its main @entity137 is the @entity8566 . To date, no predictive factors of PPE have been identified. METHODS: Data of @entity1 (pts) treated with PLD between 2005 and 2014 were retrospectively collected. A case-control study was performed, comparing main baseline clinical and biological characteristics of pts experiencing PPE and those who did not, after at least three cycles of PLD. A pilot analysis of blood monocyte subpopulations (classical, intermediate and non-classical) was performed by FACS in selected pts. RESULTS: Among 88 pts treated with PLD, 28 experienced PPE of any grade (31, 95  % CI 21-41). The first occurrence of PPE was at first cycle in only 11  % of pts, peaked at cycle 2 (32  %) and represented 57  % of cases after cycle 3. Baseline characteristics of pts with PPE were compared to 27 control pts who received at least 3 cycles. Older pts represented 61  % of pts with PPE and 15  % of pts without PPE (p  =  0.04 by Chi-square test). Monocyte count and inflammatory parameters were not associated with PPE. However, the analysis of monocyte subpopulations revealed a large inter- @entity1 variability. CONCLUSION: Contrary to most acute @entity137 , PPE occurred more frequently after several cycles, suggesting a PLD body accumulation through repeated cycles. PPE was more frequent in pts older than 70 years. Monocyte subpopulations may have different roles on PLD metabolism and warrant further studies.

Risk factors for pegylated liposomal XXXX -induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.

@entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinoma'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity8566 :: ('MESH:D060831', 'Disease') :: ['palmoplantar erythrodysesthesia (PPE) syndrome']
@entity632 :: (MESH:D004317,Chemical) :: ['doxorubicin']
